Considerations in Metastatic HER2+ Breast Cancer
Tuesday, October 13, 2020
8:00 PM-9:30 PM CDT

Pre-register and attend this event to be eligible to win an Apple Watch!

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD.

Topics of discussion at this virtual event include:

Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer

Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer

Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 

Professor and Chair,
Department of Breast Medical Oncology
UT MD Anderson Cancer Center
Houston, Texas

 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 

Neoadjuvant HER2+

SEA-22-OSD1249 - /clinical/her2-positive-neoadjuvant-care

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Webinars

® webinars feature leading oncology experts who discuss the changing landscape of various malignancies, with a focus on therapeutic considerations, new FDA-approved treatment options, multidisciplinary management, the impact of minimal residual disease in cancer care, and more. Registration of upcoming 

® webinars is complimentary and archived webinars are also available for viewing.  

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

Novel Approaches to Metastatic HER2+ Breast Cancer